题目内容
Our auditorium(礼堂) (have)（）a seating capacity of more than 3 000 people.
查看答案
搜索结果不匹配？点我反馈
更多问题
ProblemsCausesSolutions Washer Won’t start 1.Chesk the and breaker 2.Power cord may not be irmly plugged in the receptacle 1.Consult the seller 2.Make sure power cord is firmly connected What is Not supplied 1.Water tap may be closed. 2.Water supply is suspended. 3.Foreign matters may be ccumulated on the met in the mater inlet. 1.Turn on the water tap. 2.Clean the foreign matters on the net according to "maintenance". Water is not drained 1.Knob may be set to "Wash ＆Rinse". 2.Drain hose is not laid down. 3.Drain hose may be collapsed. 4.The lid may be open. 1.Set the knob to"Wash ＆Spin" . 2.Lay down the drain hose. 3.Contact the seller. 4.Close the lid. If water doesn’t flow into the washing machine, we should check whether（）first.
Growing concerns over the safety and efficacy of anti-depressant drugs prescribed to children have caught the eye of Congress and the New York state attorney general. Now they’re becoming the catalyst for calls to reform the way clinical trials of all drugs are reported. Pressure is already causing some changes within the pharmaceutical industry. And it has put the US Food and Drug Administration (FDA), which approves new drugs, in the hot seat. If reforms are carried out, they could bring an unprecedented level of transparency to drug research. The solution now under consideration: a public database, or registry, of drug trials, where companies would post the results of those trials. In congressional testimony Thursday, a spokesman for the American Medical Association endorsed the registry and said it should include information on each trial’s purpose and objective, its design, and the dates it begins and ends. If the trial is not completed, the registry should include an explanation. While drug companies have been eager to make public any positive results of their trials, recent revelations suggest they’ve balked at divulging tests when the results are not what they’d hoped to see. The furor has centered around the use Of anti-depressants on children. The industry has begun to make some moves to address the concerns about drug trials. Drug companies have agreed to set up a voluntary system of posting their drug trials on the Internet. But that seems unlikely to satisfy some members of Congress, who are expected to introduce legislation to establish a mandatory drug registry. Last week, editors of a dozen influential medical journals announced that they would begin requiring drug companies to post a drug trial in a public database prior to accepting an article about it. Doctors rely on these articles to make treatment choices. The editors hope that the registry will force unfavorable drug studies, before kept secret, into the open. Medical journals already had been tightening up on the authorship of their articles, insisting that authors declare if they had any conflicts of interest, such as any financial or other ties to the drug company, says Daniel Callahan, a director at the Hastings Center, a nonprofit bioethics research institute in Garrison, N.Y. Information from previously undisclosed clinical trials could lower prices, reduce the number of badly designed trials, and help doctors considering the use of a drug for a non-approved purpose to know why it hasn’t been approved for that use. Antidepressant drugs "have some serious side effects ... that seem to be much more common than people realize ... much more common than you might think from seeing drug ads and from reports on drug studies," says Joel Gurin, executive vice president of Consumer Reports. His magazine just finished a survey of readers showing a "dramatic shift from talk therapy to drug therapy for mental health problems" during the past decade. In 1995, less than half of people getting mental health treatment--40 percent--got drug therapy. Today 68 percent receive drug treatment, Mr. Gurin says. Some studies coming to light show that antidepressants work no better than placebos. Even better than merely registering drug trials, Caplan (director of the Center for Bioethics at the University of Pennsylvania in Philadelphia) suggests, would be to require that a new drug not only be "safe and do what it’s supposed to do", but that it do it as well or better than other drugs already on the market. That, he says, would help push research into new areas and save money. What is Caplan’s opinion in the last paragraph
某公司正准备购买一套设备，原始投资额为800万元，预计建设期为1年，另需垫支流动资金20万元。投产后每年增加销售收入280万元，付现成本65万元。该项固定资产预计使用10年，按直线法提取折旧，预计残值为50万元。该公司拟按目前产权比率为2/5的目标结构来追加资金，预计负债的利息率为12%，所得税税率为30%。公司过去没有投产过类似项目，但新项目与另一家上市公司的经营项目类似，该上市公司的β值为1.5，其资产负债率为50%，目前证券市场的无风险收益率为5%，证券市场的平均收益率为14%。[要求]计算项目的净现值，并评价项目的可行性（加权平均资本成本计算结果取整）
Growing concerns over the safety and efficacy of anti-depressant drugs prescribed to children have caught the eye of Congress and the New York state attorney general. Now they’re becoming the catalyst for calls to reform the way clinical trials of all drugs are reported. Pressure is already causing some changes within the pharmaceutical industry. And it has put the US Food and Drug Administration (FDA), which approves new drugs, in the hot seat. If reforms are carried out, they could bring an unprecedented level of transparency to drug research. The solution now under consideration: a public database, or registry, of drug trials, where companies would post the results of those trials. In congressional testimony Thursday, a spokesman for the American Medical Association endorsed the registry and said it should include information on each trial’s purpose and objective, its design, and the dates it begins and ends. If the trial is not completed, the registry should include an explanation. While drug companies have been eager to make public any positive results of their trials, recent revelations suggest they’ve balked at divulging tests when the results are not what they’d hoped to see. The furor has centered around the use Of anti-depressants on children. The industry has begun to make some moves to address the concerns about drug trials. Drug companies have agreed to set up a voluntary system of posting their drug trials on the Internet. But that seems unlikely to satisfy some members of Congress, who are expected to introduce legislation to establish a mandatory drug registry. Last week, editors of a dozen influential medical journals announced that they would begin requiring drug companies to post a drug trial in a public database prior to accepting an article about it. Doctors rely on these articles to make treatment choices. The editors hope that the registry will force unfavorable drug studies, before kept secret, into the open. Medical journals already had been tightening up on the authorship of their articles, insisting that authors declare if they had any conflicts of interest, such as any financial or other ties to the drug company, says Daniel Callahan, a director at the Hastings Center, a nonprofit bioethics research institute in Garrison, N.Y. Information from previously undisclosed clinical trials could lower prices, reduce the number of badly designed trials, and help doctors considering the use of a drug for a non-approved purpose to know why it hasn’t been approved for that use. Antidepressant drugs "have some serious side effects ... that seem to be much more common than people realize ... much more common than you might think from seeing drug ads and from reports on drug studies," says Joel Gurin, executive vice president of Consumer Reports. His magazine just finished a survey of readers showing a "dramatic shift from talk therapy to drug therapy for mental health problems" during the past decade. In 1995, less than half of people getting mental health treatment--40 percent--got drug therapy. Today 68 percent receive drug treatment, Mr. Gurin says. Some studies coming to light show that antidepressants work no better than placebos. Even better than merely registering drug trials, Caplan (director of the Center for Bioethics at the University of Pennsylvania in Philadelphia) suggests, would be to require that a new drug not only be "safe and do what it’s supposed to do", but that it do it as well or better than other drugs already on the market. That, he says, would help push research into new areas and save money. New measures of Medical journals does NOT aim at
微信支付 
支付宝支付